Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Model scores of the 29,894 trials active now.

Model score 47% for any early termination, 40% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-08-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalcellequal toradiationimaging
  Phrases that lowered it: screeningpulmonaryrespiratoryinvestigatorsigning
• Sponsor's past termination rate: 40% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 28.9% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 37 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 97.1% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 7734 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Keywords listed: 8 (lowers risk) · Design
• Has a data monitoring committee: No (raises risk) · Design
• Drug's FAERS reports before start: 32210 (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vemurafenib and White Blood Cell Therapy for Advanced Melanoma NCT01585415 · started 2012 · scored riskier than 99% of active trials terminated
• Vemurafenib and TIL Therapy for Metastatic Melanoma NCT02354690 · started 2014 · scored riskier than 94% of active trials completed
• CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma NCT02027935 · started 2015 · scored riskier than 90% of active trials completed
• The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma NCT01813214 · started 2013 · scored riskier than 97% of active trials terminated
• The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma NCT01942993 · started 2013 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.